Apremilast

Hospital Pharmacy

Volumn 49, Issue 8, 2014, Pages 752-762

  Cada, Dennis J ^a   Ingram, Kyle ^b   Baker, Danial E ^b  

^a College of Pharmacy ^*  (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APREMILAST; CARBAMAZEPINE; METHOTREXATE; PHENOBARBITAL; PHENYTOIN; PLACEBO; RIFAMPICIN;

ABDOMINAL PAIN; ADULT DISEASE; ANKYLOSING SPONDYLITIS; AREA UNDER THE CURVE; CLINICAL PHARMACOLOGY; DEPRESSION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; HUMAN; MAINTENANCE DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTICENTER STUDY (TOPIC); NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CLEARANCE; PLASMA PROTEIN BINDING; PRACTICE GUIDELINE; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SUICIDAL IDEATION; TENSION HEADACHE; UPPER RESPIRATORY TRACT INFECTION; VOLUME OF DISTRIBUTION; VOMITING;

EID: 84907204178     PISSN: 00185787     EISSN: 19451253     Source Type: Journal    
DOI: 10.1310/hpj4908-752     Document Type: Review

References (25)

1. Otezla (apremilast) [prescribing information]. Summit, NJ: Celgene Corporation; March 2014.
2. Pathan E, Abraham S, Van Rossen E, et al. Effi cacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis. 2013;72(9):1475-1480.
3. Papp K, Cather JC, Rosoph L, et al. Effi cacy of apremilast in the treatment of moderate to severe psoriasis: A randomized controlled trial. Lancet. 2012;380(9843):738-746.
4. Papp KA, Kaufmann R, Thaçi D, Hu C, Sutherland D, Rohane P. Effi cacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: Results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol. 2013;27(3):e376-e383.
5. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583-1590.
6. Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates antiinfl ammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842-855.
7. Gottlieb AB, Strober B, Krueger JG, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-infl ammatory agent, apremilast. Curr Med Res Opin. 2008;24(5):1529-1538.
8. Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012;64(10):3156-3167.
9. Hoffmann M, Kumar G, Schafer P, et al. Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration. Xenobiotica. 2011;41(12):1063-1075
10. Volf EM, Au SC, Dumont N, Scheinman P, Gottlieb AB. A phase 2, open-label, investigator-initiated study to evaluate the safety and effi cacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J Drugs Dermatol. 2012;11(3):341-346.
11. McCann FE, Palfreeman AC, Andrews M, et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther. 2010;12(3):R107.
12. Wu A, Rohane P, Ng J, et al. Safety/tolerability and pharmacokinetics of multiple oral doses of apremilast in healthy male subjects [abstract]. Clin Pharmacol Ther. 2012;91:S26.
13. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidencebased conclusions. J Am Acad Dermatol. 2011;65(1):137-174.
14. Reich K, Papp K, Leonardi C, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase III, randomized, controlled trial (ESTEEM 1) [abstract]. J Eur Acad Dermatol. 2013;27(Suppl 4):22.
15. Study to evaluate safety and effectiveness of oral apremilast (CC-10004) in patients with moderate to severe plaque psoriasis (ESTEEM 1). ClinicalTrials.gov Web site. http://www.clinicaltrials.gov/ct2/show/NCT01194219. Accessed April 8, 2014.
16. Schett G, Mease PJ, Gladman DD, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in physical function in patients with psoriatic arthritis: Results from three phase 3, randomized, controlled trials [abstract]. Arthritis Rheum. 2013;65(10):S143.
17. Cutolo M, Mease PJ, Gladman DD, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with longterm (52-week) improvement in tender and swollen joint counts in patients with psoriatic arthritis: Results from three phase 3, randomized, controlled trials [abstract]. Arthritis Rheum. 2013;65(10):S135.
18. Cutolo M, Myerson GE, Fleischmann RM, et al. Longterm (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 2) [abstract]. Arthritis Rheum. 2013;65(10):S346-S347.
19. Mease PJ, Kavanaugh A, Galdman DD, et al. Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: Pooled safety analysis of three phase 3, randomized, controlled trials [abstract]. Arthritis Rheum. 2013;65(10):S131.
20. Mease PJ, Kavanaugh A, Adebajo AO, et al. Laboratory abnormalities in patients with psoriatic arthritis receiving apremilast, an oral phosphodiesterase 4 inhibitor: Pooled safety analysis of three phase 3, randomized, controlled trials [abstract]. Arthritis Rheum. 2013;65(10):S151.
21. Edwards CJ, Blanco FJ, Crowley J, et al. Long-term (52 week) results of a phase 3 randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement (PALACE 3) [abstract]. Arthritis Rheum. 2013;65(10):S132.
22. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebocontrolled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020-1026.
23. Adebajo AO, Kavanaugh A, Mease PJ, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: Results of a phase 3, randomized, controlled trial (PALACE 1) [abstract]. J Eur Acad Dermatol Vernereol. 2013;27(suppl 4):53-54.
24. Wells AF, Edwards CJ, Adebajo AO, et al. Apremilast in the treatment of DMARD-naive psoriatic arthritis patients: Results of a phase 3 randomized, controlled trial (PALACE 4) [abstract]. Arthritis Rheum. 2013;65(12):3320-3321.
25. Parks MH. NDA approval letter: Otezla (apremilast NDA 205437). US Food and Drug Administration Web site. http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2014/20 5437Orig1s000ltr.pdf. Published March 21, 2014. Accessed March 31, 2014.